To next address whether targeting MEK/MAPK signaling pathway would enhance the anticancer activity of mTOR inhibitors, we treated LS174T and SW480 colon cancer cells with U0126 [28], a MEK inhibitor, in combination or not with mTOR inhibitors. Here, MAP2K7 is linked to malignant colon neoplasm.